Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Bicycle Therapeutics

    NASDAQ: BCYC · Real-Time Price · USD
    7.66
    -0.38 (-4.73%)
    At close: Jun 17, 2025, 3:59 PM

    Bicycle Therapeutics Statistics

    Share Statistics

    Bicycle Therapeutics has 69.2M shares outstanding. The number of shares has increased by 61.99% in one year.

    Shares Outstanding

    n/a
    		 69.2M

    Shares Change (YoY)

    n/a
    		 61.99%

    Shares Change (QoQ)

    n/a
    		 0.07%

    Owned by Institutions (%)

    n/a
    		 60.72%

    Shares Floating

    n/a
    		 61.47M

    Failed to Deliver (FTD) Shares

    n/a
    		 9,773

    FTD / Avg. Volume

    n/a
    		 2.77%

    Short Selling Information

    The latest short interest is 3.45M, so 4.98% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.45M

    Short % of Shares Out

    n/a
    		 4.98%

    Short % of Float

    n/a
    		 9.5%

    Short Ratio (days to cover)

    n/a
    		 14.16

    Valuation Ratios

    The PE ratio is -48.21 and the forward PE ratio is -1.89. Bicycle Therapeutics's PEG ratio is 0.51.

    PE Ratio

    n/a
    		 -48.21

    Forward PE

    n/a
    		 -1.89

    PS Ratio

    n/a
    		 231.02

    Forward PS

    n/a
    		 0.9

    PB Ratio

    n/a
    		 10.28

    P/FCF Ratio

    n/a
    		 -49.1

    PEG Ratio

    n/a
    		 0.51
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Bicycle Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 13.81, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 13.81

    Quick Ratio

    n/a
    		 13.81

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.06

    Debt / FCF

    n/a
    		 -0.06

    Interest Coverage

    n/a
    		 -121.31

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $115,655.74

    Profits Per Employee

    n/a
    		 $-554,200

    Employee Count

    n/a
    		 305

    Asset Turnover

    n/a
    		 0.04

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -4.76M

    Effective Tax Rate

    n/a
    		 2.74%

    Stock Price Statistics

    The stock price has increased by -63.62% in the last 52 weeks. The beta is 1.47, so Bicycle Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.47

    52-Week Price Change

    n/a
    		 -63.62%

    50-Day Moving Average

    n/a
    		 8.1

    200-Day Moving Average

    n/a
    		 15.27

    Relative Strength Index (RSI)

    n/a
    		 43.92

    Average Volume (20 Days)

    n/a
    		 352,450

    Income Statement

    In the last 12 months, Bicycle Therapeutics had revenue of 35.27M and earned -169.03M in profits. Earnings per share was -0.29.

    Revenue

    n/a
    		 35.27M

    Gross Profit

    n/a
    		 28.11M

    Operating Income

    n/a
    		 -209.87M

    Net Income

    n/a
    		 -169.03M

    EBITDA

    n/a
    		 -164.89M

    EBIT

    n/a
    		 -172.07M

    Earnings Per Share (EPS)

    n/a
    		 -0.29
    Full Income Statement

    Balance Sheet

    The company has 879.52M in cash and 9.49M in debt, giving a net cash position of 870.03M.

    Cash & Cash Equivalents

    n/a
    		 879.52M

    Total Debt

    n/a
    		 9.49M

    Net Cash

    n/a
    		 870.03M

    Retained Earnings

    n/a
    		 -680.79M

    Total Assets

    n/a
    		 883.89M

    Working Capital

    n/a
    		 798.46M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -164.72M and capital expenditures -1.24M, giving a free cash flow of -165.96M.

    Operating Cash Flow

    n/a
    		 -164.72M

    Capital Expenditures

    n/a
    		 -1.24M

    Free Cash Flow

    n/a
    		 -165.96M

    FCF Per Share

    n/a
    		 -0.29
    Full Cash Flow Statement

    Margins

    Gross margin is 79.7%, with operating and profit margins of -594.96% and -479.18%.

    Gross Margin

    n/a
    		 79.7%

    Operating Margin

    n/a
    		 -594.96%

    Pretax Margin

    n/a
    		 -492.69%

    Profit Margin

    n/a
    		 -479.18%

    EBITDA Margin

    n/a
    		 -467.45%

    EBIT Margin

    n/a
    		 -594.96%

    FCF Margin

    n/a
    		 -470.47%

    Dividends & Yields

    BCYC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BCYC is $24, which is 198.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $24

    Price Target Difference

    n/a
    		 198.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 11
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.5

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist